Tumor-bearing mice were used to investigate the antitumor activity of PRLR-DbsAb treatment with intraperitoneal (i.p) injection because there is no differences in the peak plasma concentrations between i.p and i.v administration of antibody in mice [39] and i.p administration is relatively easy to perform the in vivo experiment. Here, PRLR is linked to neoplasm.